Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial

Blood (2024) 144 (Supplement 1): 1859.

https://doi.org/10.1182/blood-2024-200903

Published: 2024

Journal Articles

Real World Patient Diagnostic and Treatment Patterns in Marginal Zone Lymphoma (MZL): First Results of the Prospective National MZL Registry of the German Lymphoma Alliance

Blood (2024) 144 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2024-200798

Published: 2024

Journal Articles

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Blood (2023) 142 (Supplement 1): 4539.

https://doi.org/10.1182/blood-2023-180730

Published: 2023

Journal Articles

IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial

Blood (2023) 142 (Supplement 1): 1903.

https://doi.org/10.1182/blood-2023-179767

Published: 2023

Journal Articles

Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial

Armin Riecke, Eugen Tausch, Deyan Y. Yosifov, Christof Schneider, Sandra Robrecht, Adam Giza, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Barbara F. Eichhorst, Kirsten Fischer, Michael Hallek, Petra Langerbeins, Stephan Stilgenbauer

Blood (2023) 142 (Supplement 1): 199.

https://doi.org/10.1182/blood-2023-180558

Published: 2023

Journal Articles

Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

Blood (2022) 140 (Supplement 1): 947–949.

https://doi.org/10.1182/blood-2022-159412

Published: 2022

Journal Articles

Diagnosis and Treatment of MPN in Real Life - Interim-Analysis of an Exploratory Chart Review on 960 ET and MF Patients in Germany

Andreas Schmidt, Christiane Bernhardt, Anette Fries, Kathleen Jentsch-Ulrich, Andreas Josting, Stephan Kreher, Marcel Reiser, H. Tilman Steinmetz, Hans Tesch, Bernhard Kaufmann, Uta Rager, Carl C. Crodel, Francesca Palandri, Florian H. Heidel

Blood (2022) 140 (Supplement 1): 9698–9699.

https://doi.org/10.1182/blood-2022-157980

Published: 2022

Journal Articles

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 5 th Interim Analysis of the Study RISA, with Special Consideration of Treatment Discontinuations

Oliver Meyer, Rudolf Schlag, Thomas Stauch, Bastian Fleischmann, Marcel Reiser, Dietrich Kaempfe, Timo Behlendorf, Manfred Welslau, Eyck von der Heyde, Steffen Dörfel, Claudia Willy, Martina Stauch

Blood (2022) 140 (Supplement 1): 2683–2684.

https://doi.org/10.1182/blood-2022-166741

Published: 2022

Journal Articles

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

Blood (2022) 139 (2): 177–187.

https://doi.org/10.1182/blood.2021010845

Published: 2022

Includes: Supplemental data

Journal Articles

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 4 th Interim Analysis of the German Non-Interventional Trial RISA

Oliver Meyer, Rudolf Schlag, Thomas Stauch, Bastian Fleischmann, Marcel Reiser, Dietrich Kaempfe, Timo Behlendorf, Manfred Welslau, Claudia Willy, Martina Stauch

Blood (2021) 138 (Supplement 1): 3150.

https://doi.org/10.1182/blood-2021-146809

Published: 2021

Journal Articles

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 3 rd Interim Analysis of the German Non-Interventional Trial RISA

Oliver Meyer, MD PhD, Martina Stauch, Dietrich Kaempfe, MD, Rudolf Schlag, Marcel Reiser, Eyck von der Heyde, Andreas Josting, Margarete Plath, Nadine Ballerstädt, Petra Stark-Lorenzen, Axel Matzdorff, MDPhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-134542

Published: 2020

Journal Articles

Cytoreductive Treatment in 'Real Life' - Interim-Analysis of 434 Polycythemia Vera Patients in Germany

Carl C. Crodel, Kathleen Jentsch-Ulrich, MD, Lutz Jacobasch, Philipp Kiewe, Jens Kisro, Jörg Lipke, Siegfried W. Prenninger, Marcel Reiser, Regine Wunschel, Andreas Hochhaus, MD, Florian H. Heidel

Blood (2019) 134 (Supplement_1): 1672.

https://doi.org/10.1182/blood-2019-122681

Published: 2019

Journal Articles

Suboptimal dosing of rituximab in male and female patients with DLBCL

Michael Pfreundschuh, Carsten Müller, Samira Zeynalova, Evelyn Kuhnt, Martin H. J. Wiesen, Gerhard Held, Tanja Rixecker, Viola Poeschel, Carsten Zwick, Marcel Reiser, Norbert Schmitz, Niels Murawski

Blood (2014) 123 (5): 640–646.

https://doi.org/10.1182/blood-2013-07-517037

Published: 2014

Includes: Supplemental data

Journal Articles

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

Carsten Müller, Niels Murawski, Martin H. J. Wiesen, Gerhard Held, Viola Poeschel, Samira Zeynalova, Michael Wenger, Christina Nickenig, Norma Peter, Eva Lengfelder, Bernd Metzner, Tanja Rixecker, Carsten Zwick, Michael Pfreundschuh, Marcel Reiser

Blood (2012) 119 (14): 3276–3284.

https://doi.org/10.1182/blood-2011-09-380949

Published: 2012

Journal Articles

Improved Outcome of Elderly Poor-Prognosis DLBCL Patients with 6xCHOP-14 and 8 Applications of Rituximab (R) Given Over An Extended Period: Results of the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

Michael Pfreundschuh, MD, Gerhard Held, Samira Zeynalova, Viola Pöschel, Andreas Viardot, MD, Matthias Hänel, MD, Ulrich Keller, MD, Marcel Reiser, MD, Markus Löffler, Niels Murawski, MD

Blood (2011) 118 (21): 592.

https://doi.org/10.1182/blood.V118.21.592.592

Published: 2011

Journal Articles

Male Sex Is Associated with Lower Rituximab Trough Serum Levels and Evolves as a Significant Prognostic Factor in Elderly Patients with DLBCL Treated with R-CHOP: Results From 4 Prospective Trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL).

Michael Pfreundschuh, Niels Murawski, Samira Zeynalova, Viola Poeschel, Marcel Reiser, Anthony D. Ho, Christina Nickenig, Swen Wessendorf, Bernd Metzner, Sandra Grass, Joerg Schubert, Markus Loeffler, Norbert Schmitz

Blood (2009) 114 (22): 3715.

https://doi.org/10.1182/blood.V114.22.3715.3715

Published: 2009

Journal Articles

The Role of Radiotherapy to Bulky Disease in the Rituximab Era: Results from Two Prospective Trials of the German High-Grade Non-Hodgkin- Lymphoma Study Group (DSHNHL) for Elderly Patients with DLBCL

Michael Pfreundschuh, MD, Marita Ziepert, Marcel Reiser, Viola Poeschel, Sibylla Wilhelm, Tobias Gaska, Michael Heike, Norbert Schmitz, Christian Ruebe, Markus Loeffler, Joerg Schubert

Blood (2008) 112 (11): 584.

https://doi.org/10.1182/blood.V112.11.584.584

Published: 2008

Journal Articles

Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma: Long Term Follow up of a Randomized Trial of the

Martin H. Dreyling, MD, Eva Hoster, PhD, Achiel Van Hoof, Bernd Metzner, Christian Gisselbrecht, Michael Pfreundschuh, MD, PhD, Marcel Reiser, Lorenz H. Truemper, MD, PhD, Hjalmar Steinhauer, Jean-Michel Boiron, MD, PhD, Marc Boogaerts, MD, PhD, Vittorio Silingardi, J.C. Kluin- Nelemans, MD, PhD, Michael Unterhalt, Wolfgang Hiddemann

Blood (2008) 112 (11): 769.

https://doi.org/10.1182/blood.V112.11.769.769

Published: 2008

Journal Articles

Autologous Stem Cell Transplantation after Myeloablative Therapy in First Remission May Be Beneficial in Patients with Advanced Stage Follicular Lymphoma after Front-Line Therapy with R-CHOP. An Analysis of Two Consecutive Studies of the German Low Grade Lymphoma Study Group (GLSG)

Wolfgang Hiddemann, Christian Buske, Michael Kneba, MD, PhD, Martin Dreyling, Norbert Schmitz, Eva Lengfelder, Rudolf Schmits, Marcel Reiser, Bernd Metzner, Michael Unterhalt, PhD

Blood (2008) 112 (11): 772.

https://doi.org/10.1182/blood.V112.11.772.772

Published: 2008

Journal Articles

Relapse of Central Nervous System Lymphoma after systemic Lymphoma (SCNSL): Clinical Features and Outcome as compared to Primary CNS Lymphoma (PCNSL) Patients

Blood (2008) 112 (11): 3602.

https://doi.org/10.1182/blood.V112.11.3602.3602

Published: 2008

NARROW

Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial

Real World Patient Diagnostic and Treatment Patterns in Marginal Zone Lymphoma (MZL): First Results of the Prospective National MZL Registry of the German Lymphoma Alliance

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial

Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial

Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

Diagnosis and Treatment of MPN in Real Life - Interim-Analysis of an Exploratory Chart Review on 960 ET and MF Patients in Germany

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 5 th Interim Analysis of the Study RISA, with Special Consideration of Treatment Discontinuations

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 4 th Interim Analysis of the German Non-Interventional Trial RISA

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 3 rd Interim Analysis of the German Non-Interventional Trial RISA

Cytoreductive Treatment in 'Real Life' - Interim-Analysis of 434 Polycythemia Vera Patients in Germany

Suboptimal dosing of rituximab in male and female patients with DLBCL

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

Improved Outcome of Elderly Poor-Prognosis DLBCL Patients with 6xCHOP-14 and 8 Applications of Rituximab (R) Given Over An Extended Period: Results of the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

Male Sex Is Associated with Lower Rituximab Trough Serum Levels and Evolves as a Significant Prognostic Factor in Elderly Patients with DLBCL Treated with R-CHOP: Results From 4 Prospective Trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL).

The Role of Radiotherapy to Bulky Disease in the Rituximab Era: Results from Two Prospective Trials of the German High-Grade Non-Hodgkin- Lymphoma Study Group (DSHNHL) for Elderly Patients with DLBCL

Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma: Long Term Follow up of a Randomized Trial of the

Autologous Stem Cell Transplantation after Myeloablative Therapy in First Remission May Be Beneficial in Patients with Advanced Stage Follicular Lymphoma after Front-Line Therapy with R-CHOP. An Analysis of Two Consecutive Studies of the German Low Grade Lymphoma Study Group (GLSG)

Relapse of Central Nervous System Lymphoma after systemic Lymphoma (SCNSL): Clinical Features and Outcome as compared to Primary CNS Lymphoma (PCNSL) Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only